1. Home
  2. KOS vs AVXL Comparison

KOS vs AVXL Comparison

Compare KOS & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$1.48

Market Cap

475.3M

Sector

Energy

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.14

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
AVXL
Founded
2003
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
475.3M
397.6M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
KOS
AVXL
Price
$1.48
$4.14
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$1.76
$22.00
AVG Volume (30 Days)
18.3M
1.4M
Earning Date
03-02-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,392,234,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$2.86
52 Week High
$3.49
$13.99

Technical Indicators

Market Signals
Indicator
KOS
AVXL
Relative Strength Index (RSI) 51.14 33.16
Support Level $1.28 $3.81
Resistance Level $1.54 $5.05
Average True Range (ATR) 0.12 0.28
MACD -0.01 -0.14
Stochastic Oscillator 21.70 2.58

Price Performance

Historical Comparison
KOS
AVXL

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: